Dr. Baz has developed a special expertise in managing patients with plasma cell disorders such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, primary systematic amyloidosis, and Waldenstrom's macroglobulinemia (WM). Dr. Baz is a very active researcher in the field and is involved in a number of clinical trials as well as the Moffitt Myeloma Working Group (MMWG). He is a frequent lecturer on myeloma for both medical and lay audiences. Dr. Baz’s research focuses on malignant hematology and involves the development and implementation of biomarker-driven therapeutics into patient-based phase I and II clinical trials, including early-phase clinical trials in multiple myeloma. In this context, he and his colleagues initiated a clinical trial of a response-adapted therapy in newly diagnosed myeloma patients who are not candidates for high-dose therapy and do not have high-risk disease. He and his team are evaluating several novel agents (novel proteasome inhibitors, novel immunomodulators as well as monoclonal antibodies). Moreover, Dr. Baz has collaborated with outcome researchers (focusing on outcomes to therapy as well as defining optimal sequences of therapy) and with basic scientists (focusing on translational research and new drug development in myeloma).

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811